RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Bone Cancer
  Breast Cancer
  Cervical Cancer
  Gastric Cancer
  Liver Cancer
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Testicular Cancer
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Therapy Channel

subscribe to Therapy newsletter
Latest Research : Cancer : Therapy

   EMAIL   |   PRINT
Oral chemotherapy option soon for cancer

Apr 18, 2006 - 7:20:00 AM , Reviewed by: Priya Saxena
"Full results from the study have been submitted to the American Society of Clinical Oncology (ASCO) for presentation at their annual meeting taking place from June 2-6 in Atlanta, the US,"

[RxPG] Swiss pharmaceutical major Roche's study investigating Xeloda (capecitabine) in the first-line treatment of advanced stomach cancer has successfully met its primary endpoint, the company said Monday.

Data from the first-ever phase III clinical study showed that Xeloda, added to another chemotherapy called cisplatin, was at least as effective as the current standard treatment - that uses intravenous 5-fluorouracil plus cisplatin - in terms of time to disease progression, Roche said in a statement.

This international study was a randomised, open-label one of the effect of first-line chemotherapy with Xeloda plus cisplatin versus intravenous 5-fluorouracil plus cisplatin on time to disease progression in patients with advanced or metastatic gastric cancer.

Gastric cancer is the fourth most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide. It affects twice as many men as women and occurs more frequently in people aged over 55 years.

Xeloda is licensed in more than 90 countries including the EU, the US, Japan, Australia, Canada and India and has been shown to be an effective, safe, simple and convenient oral chemotherapy.

The oncology market in India is estimated at $30 million. Other cancer drugs from Roche in India include Herceptin and Avastin.

"Full results from the study have been submitted to the American Society of Clinical Oncology (ASCO) for presentation at their annual meeting taking place from June 2-6 in Atlanta, the US," the statement said.

Based on the results of the study, Roche plans to file for an indication in advanced gastric cancer with worldwide regulatory authorities, the company said.

Publication: Indo-Asian News Service

Advertise in this space for $10 per month. Contact us today.

Related Therapy News
Taccalonolides from bat plants selectively kill cancer cells
Photodynamic therapy can help preserve the voice for patients with early stage laryngeal cancer
Bionic Nose to Detect Cancers
Anti- cancer gene discovered- new strategy for treatment?
Anthracycline induced heart damage can be reduced by prolonging infusion time
Genomic signatures to guide the use of chemotherapeutics
CDK2/FOXO1 as drug target to Prevent Tumors
Telomerase inhibitors may revolutionize cancer therapy
First ever shots of the cervical cancer vaccine administered in Queensland
Gleevec can be toxic to the heart

Subscribe to Therapy Newsletter

Enter your email address:

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)